Here's Why Viking Therapeutics Shares Slumped Today

Viking Therapeutics (VKTX) dropped 14.5% following the announcement of a $500 million capital raise—$275 million in common stock and $225 million in convertible notes. The decline came despite positive results from a maintenance study for VK2735, the company's weight-loss drug candidate, which prompted management to upsize the offering from its initial plans.

The stock traded above $41 before the announcement. The company set the common stock offering price at $35, creating immediate downward pressure as existing shareholders absorbed the dilution and near-term overhang from the convertible notes.

The capital raise was not triggered by negative clinical trial data. Instead, the maintenance study results reinforced the company's development timeline, leading management to accelerate funding for the program. The sell-off reflects mechanical selling pressure and profit-taking rather than deterioration in the drug's prospects.